A double-blind comparison of the efficacy and tolerability of telmisartan 40-80 mg vs. losartan 50-100 mg in Taiwanese hypertensive patients

Summary A multicentre, randomised, double‐blind, double‐dummy, parallel‐group, dose‐titration study was conducted to determine the efficacy and tolerability of telmisartan 40–80 mg once daily compared with losartan 50–100 mg once daily in 180 Taiwanese patients with mild‐to‐moderate essential hypertension. After an initial 2‐week placebo run‐in phase, patients were randomised in a double‐blind, double‐dummy fashion to receive either telmisartan 40 mg or losartan 50 mg. If blood pressure control (diastolic blood pressure [DBP]